-
Contact Dermatitis 06/2009; 60(5):288-9. · 3.51 Impact Factor
-
Contact Dermatitis 03/2009; 60(2):113-4. · 3.51 Impact Factor
-
W Uter,
J Hegewald,
W Aberer,
F Ayala,
A J Bircher,
J Brasch,
P-J Coenraads,
M-L A Schuttelaar,
P Elsner,
M Fartasch, [......],
J D Johansen,
T Menné,
R Jolanki,
B Krêcisz,
M Kiec-Swierczynska,
F Larese, D Orton,
A Peserico,
T Rantanen,
A Schnuch
[show abstract]
[hide abstract]
ABSTRACT: Since January 2001, the European Surveillance System on Contact Allergies (ESSCA), supported by European Union funding (contract QLK4-CT-2001-00343), has started to collect patch-test data. This comprises a standardized clinical history and the patch-test results using the European standard series, from 17 centres in 9 European countries listed above. In 2002 and 2003, 10 511 patients' test results have been pooled and analysed. The anamnestic data partly reflect the subspecialties of some centres. The most common allergen was nickel sulfate (17.3%); however, large international variations were observed. The prevalence of contact allergy to Myroxylon pereirae resin (balsam of Peru) (5.8%) is coming close to the frequency found with the fragrance mix (6.4%). Regarding contact allergy to chromium compounds, different frequencies were noted in the 2 centres focused on occupational dermatitis (2.3% in the FIOH versus 7.4% in the Nofer Institute). These most likely reflect the beneficial effect of addition of ferrous sulfate in one, but not the other country. As differences may partly be due to different patch-test reading, standardization may need to be refined further. By providing post-marketing surveillance in the field of contact allergy, ESSCA will meet its objective of increased consumer safety across Europe.
Contact Dermatitis 10/2005; 53(3):136-45. · 3.51 Impact Factor
-
B Gruvberger,
K E Andersen,
F M Brandão,
D P Bruynzeel,
M Bruze,
P J Frosch,
A Goossens,
A Lahti,
M Lindberg,
T Menné, D Orton,
S Seidenari
[show abstract]
[hide abstract]
ABSTRACT: Contact allergy to and allergic contact dermatitis from methyldibromo glutaronitrile (MDBGN) have frequently been reported. As there has been no agreement on which MDBGN test preparation to use, a study was initiated to help determine the optimal patch test preparation for MDBGN. 2661 consecutively patch tested patients at 11 test clinics representing 9 European countries participated. Petrolatum preparations with MDBGN at 1.0%, 0.5%, 0.3% and 0.1% were inserted in the standard series. Contact allergy rates were noted in the range 4.4-1.1% following decreasing test concentrations. Reactions not fulfilling all criteria to be classified as allergic reactions could represent either weak allergic or irritant reactions, and such reactions were noted in the range 8.2-0.5% with decreasing concentrations. A significant number of these reactions represented weak allergic reactions, as allergic reactions were obtained to higher patch test concentrations in the same individual. Morphologically irritant reactions were noted only for the highest test concentrations. In summary, the contact allergy rates and frequencies of doubtful and irritant reactions vary with the patch test concentration. The final decision on patch test concentration for MDBGN should not only rely on these factors but also include information on patch test concentrations required to diagnose individual cases with allergic contact dermatitis from MDBGN as well as results of repeated open application tests.
Contact Dermatitis 02/2005; 52(1):14-8. · 3.51 Impact Factor
-
B Gruvberger,
K E Andersen,
F M Brandão,
D P Bruynzeel,
M Bruze,
P J Frosch,
A Goossens,
A Lahti,
H I Maibach,
T Menné, D Orton,
S Seidenari
[show abstract]
[hide abstract]
ABSTRACT: Contact allergy to and allergic contact dermatitis from methyldibromo glutaronitrile (MDBGN) have frequently been reported. This study was initiated to help determine the optimal patch test preparation for MDBGN. In 51 patients with a doubtful or a positive patch test reaction to at least 1 of 4 test preparations with MDBGN in petrolatum at 1.0% w/w, 0.5%, 0.3% and 0.1%, a repeated open application test (ROAT) with moisturizers with and without MDBGN at 0.03% w/w was performed on the upper arms for 2 weeks. 18 of the 51 (35.3%) patients developed a positive ROAT. In all patients, there was a positive ROAT only to the moisturizer with MDBGN (P < 0.001). A statistically significant association was also found between the patch test reactivity (PTRL) and the outcome of the ROAT (P < 0.001). If only considering those with a PTRL above 0.3%, thus with negative or doubtful test reactions to 0.1% and 0.3%, there were still statistically significantly more patients with a positive ROAT to the moisturizer with MDBGN than to the moisturizer without MDBGN. The study demonstrates that patch testing with MDBGN at 0.3% and 0.1% will miss clinically relevant patch test reactions to MDBGN.
Contact Dermatitis 01/2005; 52(1):19-23. · 3.51 Impact Factor
-
Contact Dermatitis 06/2002; 46(5):311-2. · 3.51 Impact Factor
-
Contact Dermatitis 09/2001; 45(2):123. · 3.51 Impact Factor
-
Contact Dermatitis 51(5-6):314-5. · 3.51 Impact Factor
